scholarly journals Regulation of the Expression of Peptidylarginine Deiminase Type II Gene (PADI2) in Human Keratinocytes Involves Sp1 and Sp3 Transcription Factors

2005 ◽  
Vol 124 (5) ◽  
pp. 1026-1033 ◽  
Author(s):  
Sijun Dong ◽  
Toshio Kojima ◽  
Masakazu Shiraiwa ◽  
Marie-Claire Méchin ◽  
Stéphane Chavanas ◽  
...  
Keyword(s):  
Transcription Factors ◽  
Human Keratinocytes ◽  
Type Ii ◽  
Peptidylarginine Deiminase

scholarly journals Existence and Differential Changes of Peptidylarginine Deiminase Type II in Mouse Yolk-Sac Erythroid Cells

1995 ◽  
Vol 59 (3) ◽  
pp. 552-554 ◽  
Author(s):  
Hiroko Koike ◽  
Masakazu Shiraiwa ◽  
Kiyoshi Sugawara ◽  
Tetsuya Kohsaka ◽  
Hidenari Takahara
Keyword(s):  
Yolk Sac ◽  
Type Ii ◽  
Erythroid Cells ◽  
Peptidylarginine Deiminase

scholarly journals Conservation of the sizes of 53 introns and over 100 intronic sequences for the binding of common transcription factors in the human and mouse genes for type II procollagen (COL2A1)

1995 ◽  
Vol 308 (3) ◽  
pp. 923-929 ◽  
Author(s):  
L Ala-Kokko ◽  
A P Kvist ◽  
M Metsäranta ◽  
K I Kivirikko ◽  
B de Crombrugghe ◽  
...  
Keyword(s):  
Transcription Factors ◽  
Type Ii ◽  
Stem Loop ◽  
Col2a1 Gene ◽  
Conserved Sequences ◽  
Consensus Sequences ◽  
Rna Transcripts ◽  
First Intron ◽  
Intron 2 ◽  
Human And Mouse

Over 11,000 bp of previously undefined sequences of the human COL2A1 gene were defined. The results made it possible to compare the intron structures of a highly complex gene from man and mouse. Surprisingly, the sizes of the 53 introns of the two genes were highly conserved with a mean difference of 13%. After alignment of the sequences, 69% of the intron sequences were identical. The introns contained consensus sequences for the binding of over 100 different transcription factors that were conserved in the introns of the two genes. The first intron of the gene contained 80 conserved consensus sequences and the remaining 52 introns of the gene contained 106 conserved sequences for the binding of transcription factors. The 5′-end of intron 2 in both genes had a potential for forming a stem loop in RNA transcripts.

Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin

2002 ◽  
Vol 407 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Akihito Ishigami ◽  
Takako Ohsawa ◽  
Hiroaki Asaga ◽  
Kyoichi Akiyama ◽  
Masashi Kuramoto ◽  
...  
Keyword(s):  
Molecular Cloning ◽  
Human Skin ◽  
Gene Organization ◽  
Type Ii ◽  
Peptidylarginine Deiminase

scholarly journals Peptidylarginine deiminase type I, type II, type III and type IV are expressed in rat epidermis

2001 ◽  
Vol 22 (1) ◽  
pp. 63-65 ◽  
Author(s):  
AKIHITO ISHIGAMI ◽  
HIROAKI ASAGA ◽  
TAKAKO OHSAWA ◽  
KYOICHI AKIYAMA ◽  
NAOKI MARUYAMA
Keyword(s):  
Type I ◽  
Type Ii ◽  
Peptidylarginine Deiminase ◽  
Type Iii ◽  
Type Iv

Increased peptidylarginine deiminase type II in hypoxic astrocytes

2004 ◽  
Vol 325 (4) ◽  
pp. 1324-1329 ◽  
Author(s):  
Thiagarajan Sambandam ◽  
Maria Belousova ◽  
Mary Ann Accaviti-Loper ◽  
Carmelo Blanquicett ◽  
Vincenzo Guercello ◽  
...  
Keyword(s):  
Type Ii ◽  
Peptidylarginine Deiminase

scholarly journals Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors

2001 ◽  
Vol 360 (2) ◽  
pp. 461-470 ◽  
Author(s):  
David G. STOKES ◽  
Gang LIU ◽  
Rita DHARMAVARAM ◽  
David HAWKINS ◽  
Sonsoles PIERA-VELAZQUEZ ◽  
...  
Keyword(s):  
Transcription Factors ◽  
High Mobility ◽  
Type Ii Collagen ◽  
Culture Conditions ◽  
High Mobility Group ◽  
Collagen Gene ◽  
Type Ii ◽  
Reporter Construct ◽  
Monolayer Cultures

During ex vivo growth as monolayer cultures, chondrocytes proliferate and undergo a process of de-differentiation. This process involves a change in morphology and a change from expression of chondrocyte-specific genes to that of genes that are normally expressed in fibroblasts. Transfer of the monolayer chondrocyte culture to three-dimensional culture systems induces the cells to re-acquire a chondrocyte-specific phenotype and produce a cartilaginous-like tissue in vitro. We investigated mechanisms involved in the control of the de-differentiation and re-differentiation process in vitro. De-differentiated chondrocytes re-acquired their chondrocyte-specific phenotype when cultured on poly-(2-hydroxyethyl methacrylate) (polyHEMA) as assayed by morphology, reverse transcriptase PCR of chondrocyte-specific mRNA, Western-blot analysis and chondrocyte-specific promoter activity. Essentially, full recovery of the chondrocyte-specific phenotype was observed when cells that had been cultured for 4 weeks on plastic were transferred to culture on polyHEMA. However, after subsequent passages on plastic, the phenotype recovery was incomplete or did not occur. The activity of a gene reporter construct containing the promoter and enhancer from the human type-II collagen gene (COL2A1) was modulated by the culture conditions, so that its transcriptional activity was repressed in monolayer cultures and rescued to some extent when the cells were switched to polyHEMA cultures. The binding of Sry-type high-mobility-group box (SOX) transcription factors to the enhancer region was modulated by the culture conditions, as were the mRNA levels for SOX9. A transfected human type-II collagen reporter construct was activated in de-differentiated cells by ectopic expression of SOX transcription factors. These results underscore the overt change in phenotype that occurs when chondrocytes are cultured as monolayers on tissue-culture plastic substrata.

scholarly journals Expression of Selected Epithelial-Mesenchymal Transition Transcription Factors in Endometrial Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Paweł Sadłecki ◽  
Jakub Jóźwicki ◽  
Paulina Antosik ◽  
Małgorzata Walentowicz-Sadłecka
Keyword(s):  
Multivariate Analysis ◽  
Endometrial Cancer ◽  
Transcription Factors ◽  
Wall Thickness ◽  
Primary Tumor ◽  
Univariate Analysis ◽  
Distant Metastases ◽  
Uterine Wall ◽  
Type Ii ◽  
Therapeutic Decisions

Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries. The aim of this study was to analyze the expression of SNAIL, SLUG, TWIST1, TWIST2, ZEB1, and ZEB 2 in primary tumor and the correlation with morphological and clinical characteristics of EC. The study included 158 patients with EC after surgical treatments: total hysterectomy and lymphadenectomy. The percentages of EC specimens testing positively for the EMT transcription factors were 84.5% for SNAIL, 92.2% for SLUG, 10.9% for TWIST1, 100% for TWIST2, 89% for ZEB1, and 98% for ZEB2. The expression of SLUG in patients with FIGO stage III or IV, type II EC, myometrial invasion ≥ 50 % of the uterine wall thickness, and adnexal involvement and in patients with distant metastases was significantly higher. SLUG and ZEB2 expressions were identified as significant predictors of higher FIGO stages (III or IV) on univariate analysis. The overexpression of SLUG was a significant predictor of more aggressive type II EC, myometrial   invasion ≥ 50 % of the uterine wall thickness, and distant metastases on both univariate and multivariate analysis. Moreover, the overexpression of SLUG and ZEB2 was shown to be significant predictors of adnexal involvement on univariate analysis. ZEB 2 overexpression was identified in multivariate analysis as another independent predictor associated with a lesser likelihood of type II EC. Both univariate and multivariate analyses demonstrated that SLUG expression was the only predictor of 5-year survival in the study group. The overexpression of SLUG was associated with a significant increase in mortality hazard on univariate analysis and was shown to be a highly significant predictor of death on multivariate analysis. Conclusions. Selected proteins of the EMT pathway play a role in endometrial carcinogenesis; SLUG and ZEB2 expressions in the primary tumor might predict clinical outcomes in EC and drive therapeutic decisions regarding adjuvant treatment in patients with this malignancy.

Sign in / Sign up

Export Citation Format

Share Document